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Managing persistent pain in secure 
settings
Introduction 
Managing persistent pain in secure environments 
presents clinicians with a number of challenges 
surrounding diagnosis, management, and measuring 
meaningful outcomes of therapy. It may also present 
a good opportunity to observe the outcomes of 
treatment. Every person in custody should have access 
to evidence-based pain management that can be safely 
delivered. To achieve this, healthcare professionals 
working in secure environments need to understand 
current best practice in diagnosing and managing the 
symptoms of persistent pain.
Clinicians working in secure environments are rightly 
concerned about the safe use of analgesic medication. 
Prescribers should work with patients with pain to 
find effective therapeutic options, but the potential 
for the drugs to be diverted and misused necessarily 
influences their decisions. Medications used for pain 
have a number of effects on the central nervous system 
that make them prone to misuse, so the prescribing 
decision must take into account the safety of the 
patient and not put him or her at risk from bullying 
and coercion. When drugs known to be misused are 
clinically indicated for the treatment of pain, appropriate 
safeguards must be put in place.
While clinicians need to understand and apply the 
principles of pharmacotherapy in managing persistent 
pain, they must also recognise that analgesic 
medication plays only a partial role in effectively 
managing long-term symptoms.
Aims of the document
The document is an overview of best practice in 
managing persistent pain and describes how this 
practice might be implemented in secure environments, 
including prisons, police custody and immigration 
removal centres. It empowers clinicians by supporting 
the evidence-based decisions they make within a 
context of multidisciplinary pain management. The 
document also acknowledges the challenges posed 
by difficult clinical presentations and the particular 
environment. It is not a comprehensive guide to 
managing all pain conditions but instead offers 
guidance with the most commonly identified challenges 
for pain management in the secure environment. It 
does not discuss interventions that can be delivered 
only in secondary care. This document complements 
Safer Prescribing in Prisons (RCGP 2011).
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1. The context
1.1 The size of the problem
No current data identifies the prevalence of pain in 
the secure environment population. A number of 
risk factors in the relatively young population (who 
may have expectations of being pain free) suggest 
that persistent pain is likely to be common. These 
factors include a high prevalence of mental health and 
substance misuse disorders (including alcohol use), 
and histories of physical and emotional trauma. Also, 
the anxiety of coming into prison may intensify an 
individual’s experience of existing pain. 
Among the prison population, 16% have 
musculoskeletal disorders, 5% have cardiovascular 
disease and 5% have neurological conditions. 
Detoxification from opioids and other drugs may 
cause previously masked pain symptoms to emerge. 
Prisoners in the high security prison estate, or serving 
long sentences elsewhere, may develop co-morbid 
long-term ill health that can contribute to their reports 
of persistent pain.
1.2 Trends in prescribing
Accurate prescribing data for analgesics is 
unavailable. It can be difficult to distinguish between 
patients who ask for medication because they are in 
pain and those who request the drugs to continue 
their substance misuse or to use as a commodity. As 
an example of the scale of analgesic prescribing, a 
snapshot from two institutions (populations 751 and 
859 respectively) suggested that between 55,000 
and more than 350,000 analgesic tablets (excluding 
paracetamol and ibuprofen) were prescribed in  
one month. 
Local compliance with national guidance on mitigation 
strategies may be limited because of difficulties in 
implementing them. This includes meeting the Prison 
Service Instruction (PSI 45/2010) that ’all abusable 
medication‘ should not be given in possession (note 
that this instruction does not affect non-abusable 
analgesics, which may be given in possession). In 
addition, advice that long-acting medications should 
be considered for first-line use may be inconsistently 
implemented. 
In community and secure environment settings, 
clinicians may lack good understanding and 
application of high-quality evidence-based pain 
management. In particular, they may not recognise the 
circumscribed role of opioid analgesics in managing 
long-term pain symptoms. This can cause them to 
lack confidence in resisting unsuitable requests for 
analgesic medication. 
Although the increased potential for misuse and 
diversion of analgesic drugs can influence clinical 
decisions in secure environments (and particularly 
prisons), these risks are sometimes balanced by the 
opportunity to monitor and regularly review patients 
and their response to the medication.
1.3 Additional challenges in specific 
settings
1.3.1 Female prison estate
Few problems or risk factors are gender-specific. 
However, female prisoners exhibit a higher prevalence 
than male prisoners of a number of risk factors 
that may contribute to pain symptoms, worsen the 
experience of pain, and act as barriers to effective 
pain management and recovery. These factors include 
histories of sexual and emotional abuse, and the 
disruption of their roles as parents. 
Many female prisoners receive relatively short 
sentences, which can interrupt consistent long-
term management of their symptoms. Prescribed 
medication misuse, particularly sedatives, is common 
among women in the community and in secure 
environments. As in male prisons, patients can be 
intimidated into diverting their personal medication. 
1.3.2 Male high-security prisons 
Serious personality disorders, often associated with 
childhood histories of abuse and trauma, are prevalent 
in male high-security prisons, but substance misuse 
disorders tend to be less common than elsewhere in 
the prison estate. Long-term medical conditions may 
have been previously poorly managed. 
The high-security prison environment is challenging, 
with prisoners potentially intimidating and 
manipulating staff as well as other prisoners. 
These prisons also have a history of inappropriate 
prescribing of abusable analgesic medications. In 
common with other secure environments, people 
who use illicit drugs and medications infrequently 
outside may begin to do so in these settings. 
Staff may feel isolated from mainstream clinical 
education and practice, and may fear criticism, 
complaints and legal claims, which can become a 
barrier to optimal prescribing. Recruiting and retaining 
staff is problematic and may lead to inconsistencies  
in care. 
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2. Clinical issues
2.1 Diagnosis and prescribing 
2.1.1 Diagnosing persistent pain
Pain is a subjective sensory and emotional experience, 
usually expressed in terms of tissue damage. In routine 
clinical practice in the community it is unusual for patients 
to use factitious pain symptoms to secure medication 
or other support. Instead, clinicians are likely to take the 
patient’s report as a starting point for investigating and 
treating the pain. However, it is difficult for an observer 
to confirm or refute such a report. Physiologic changes 
in particular, such as tachycardia, hypertension and 
sweating seen in patients with acute painful injury, are not 
features of long-term pain. Facial and other behavioural 
expression may have habituated to low levels and only 
facial expression is specific to pain. 
Although our understanding of pain is always changing 
and sophisticated techniques such as functional 
imaging give information about pain in experimental 
settings, it is generally agreed that routine investigations 
and tests may not be helpful in making a diagnosis. 
Confirming a diagnosis of persistent pain in a secure 
setting is even more challenging because the 
proportion of patients presenting with false symptoms 
to acquire analgesic medications for personal use or as 
currency is greater than in routine clinical practice in the 
community. Timely communication from the patient’s 
community healthcare team or an enquiry to them 
about existing painful conditions may provide useful 
information about long-term pain that needs continuing 
management in custody. Common antecedents of 
persistent pain may include a history of trauma or a 
defined episode of tissue damage. The symptoms 
should bear an intuitive temporal relationship with the 
putative cause and onset/exacerbation of pain. 
Persistent pain is usually accompanied by an 
observable decrement in physical, social and emotional 
function, but with possible day-to-day variation, such 
that inconsistency across time does not necessarily 
denote that the pain is not real.
2.1.2 Diagnosing neuropathic pain 
Neuropathic pain is a consequence of disease or 
damage to pain-conducting pathways, resulting in 
abnormal pain signalling in the nervous system. 
A number of well-defined neuropathic pain syndromes 
exist including diabetic neuropathy, post-herpetic 
neuralgia (pain after shingles), phantom limb pain, 
and pain following a stroke. Neuropathic pain may 
also result from damage to the nervous system from 
infection, injury or disease (e.g. multiple sclerosis). 
Epidemiological studies suggest that neuropathic pain 
is more severe and associated with a poorer quality 
of life than other types of pain. The pain can come 
on without obvious stimulus or can be evoked by a 
stimulus that is not normally painful e.g. light touch. The 
pain can be continuous or intermittent. 
Features in the patient’s history, such as a distribution of 
pain that makes anatomical sense and a relevant history 
of nerve injury or damage, can support the diagnosis. 
It is important to corroborate a suggestive history of, 
or positive screening test for, neuropathic pain with a 
physical examination that identifies abnormal function 
(i.e. numbness or hypersensitivity in the area of pain) 
or tests that demonstrate nerve injury (such as a scan 
showing nerve compression or electrophysiologic 
evidence of neuropathy). A number of screening tools for 
neuropathic pain are available (see further reading).
2.1.3 Diagnosing chronic visceral pain and poorly 
defined disorders
Chronic visceral pain occurs in men and women. 
Examples include chronic pelvic pain, irritable bowel 
syndrome, painful bladder syndrome and prostatodynia. 
There is an association with sexual and physical abuse 
in childhood and as an adult, but causality is unclear.
While terms such as prostatitis or cystitis imply a solely 
organ-based pathology, it is becoming more clear 
that central nervous system processes play a key 
role in the development of many of these conditions. 
Understanding this can help clinicians explain and 
formulate more effective treatment plans.
The context: key points
• The prevalence of long-term pain in the 
secure environment population is unknown
• Prisoners have a number of risk factors for 
chronic pain, including mental health and 
substance misuse disorders, physical and 
emotional trauma
• It can be difficult to distinguish patients who 
need medication for pain from those who 
want to misuse it or trade it as a commodity
• The secure environment offers an opportunity 
to assess regularly the effect of analgesic 
medications on pain and function
• Professional isolation and fear of criticism 
and complaints can erode confidence in 
prescribing decisions.
Managing persistent pain in secure settings
6 
2.1.4 The role of opioids in managing persistent pain
The World Health Organisation analgesic ladder 
recommends introducing more potent analgesics 
incrementally when pain does not respond to first-
line therapy. However, this tool was developed for 
managing cancer pain and is not applicable for 
managing persistent non-cancer pain. 
Little evidence exists for the effectiveness of opioids in 
treating long-term pain. In particular, there is no data 
to show that opioids improve key pain-management 
outcomes, including level of functioning, mood and 
quality of life. Given this lack of evidence for positive 
effects, the possibility of long-term harm (particularly to 
the endocrine and immune systems and risk of opioid-
induced hyperalgesia – i.e. the opioids enhance rather 
than attenuate the pain) assumes greater significance. 
Robust data shows that harms of treatment are dose 
related. In most cases, opioids should be titrated to a 
maximum of 120mg morphine equivalent per 24 hours 
for patients not currently using opioids. If there is no 
demonstrable benefit at this dose, adjusting it upwards 
is unlikely to help and the drug should be tapered and 
stopped. Opioid therapy aims to reduce the intensity of 
pain sufficiently to allow the patient to engage in self-
management strategies, which usually need additional 
physiotherapy and psychological interventions as 
described below. When patients report sustained 
benefit from opioid treatment, it is important to continue 
to advise them about the value of self-management 
strategies in the longer-term, and about the risks of 
opioid analgesia becoming less effective with time.
Opioids are traditionally classified as weak (codeine, 
dihydrocodeine) or strong (tramadol, morphine, 
oxycodone, buprenorphine, fentanyl). All should 
be prescribed with caution. A therapy trial is 
recommended whenever opioids are prescribed, 
starting with a low dose and discontinuing if, after 
suitable adjustment, pain is not relieved and improved 
function not demonstrated. 
Most cases of persistent pain should be managed with 
sustained-release preparations, again starting with a 
low dose and adjusting upwards if necessary. There is 
no evidence that any strong opioid is more effective for 
pain than another. Oral sustained-release morphine is 
a rational first-line choice if codeine or dihydrocodeine 
are ineffective. Tramadol has opioid receptor and 
monoamine effects, and might be useful in some cases 
before a morphine trial. Transdermal fentanyl patches 
are equivalent to a high daily dose of morphine (see 
table) and are not indicated for managing pain in this 
context. 
It is not usual to manage day-to-day fluctuations in pain 
intensity with immediate-release opioid preparations 
(unlike when managing breakthrough cancer-related 
pain). If a patient has infrequent intermittent symptoms 
or a varied pattern of pain intensity, this might prompt 
the use of immediate-release preparations but this 
should be discussed with a specialist. Fast-acting oral 
transmucosal, sublingual and nasal preparations are 
not recommended for treating persistent pain.
Methadone is suitable for managing persistent pain 
and its use for this indication is established practice. 
Patients with long-term pain also receiving methadone 
for substance misuse may experience pain as the 
dose reduces. Pain can be treated in this circumstance 
by maintaining an effective methadone dose. The 
pharmacokinetics of methadone mean that once-daily 
dosing is unsuitable for managing pain and it should 
instead be given as a twice-daily divided dose. 
When changing from one opioid to another, 
equianalgesic conversion ratios are a guide only. They 
are derived from single dose studies and have poor 
applicability to chronic use. Incomplete cross-tolerance 
between opioids when they are switched can lead to a 
risk of overdosing. Conversion ratios for methadone are 
unpredictable and vary several-fold when converting 
from a non-methadone opioid depending on the 
starting dose of original opioid and the duration of 
treatment. Also note that conversion ratios between 
methadone and other opioids are not bidirectional so 
should not be used to convert from methadone to 
another drug. 
Diagnosing pain: key points
• Pain is a subjective experience and can only be 
diagnosed by interpreting the patient’s report
• Good communication with the patient’s 
community healthcare team can help to 
identify pre-existing painful conditions
• The onset of pain is often related to an obvious 
inciting event, such as trauma or other tissue 
damage
• Pain is usually associated with an observable 
(but variable) decrement in physical functioning
• The history (nerve injury or damage) and any 
abnormal findings on sensory examination can 
support the diagnosis of neuropathic pain
• Understanding the complexity of origin of 
visceral pain and of poorly defined disorders 
can help to plan realistic interventions.
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In summary, conversion should use the most 
conservative ratio (i.e. the one that gives the lowest 
estimated dose of the new opioid), and incorporate a 
modest dose reduction provided that early review (within 
48 hours) is available for further dose adjustment.
2.1.5 Pharmacological management of neuropathic 
pain  
Neuropathic pain is difficult to treat. Medications are 
probably the most effective intervention but fewer than 
a third of patients respond to any given drug. Different 
classes of drug have distinct and relevant mechanisms 
of action, so if the first class tried does not work it is 
helpful to try an alternative. Pain reduction with all types 
is modest, with most lessening the intrusiveness of pain 
rather than providing substantial relief.
Drug choices for neuropathic pain should be based 
on evidence for efficacy. A number of drug classes (of 
equivalent efficacy) are available and the decision must 
reflect the safety of the drug in relation to the potential 
adverse effects as well as the specific risks related to 
the prescribing context. 
Published evidence suggests that tricyclic 
antidepressants (given as a once-daily dose) are the 
most effective first-line treatment for neuropathic pain 
(see further reading – Finnerup et al). Carbamazepine is 
also effective. Gabapentin and pregabalin are effective 
in some cases but should not be used first line in this 
context because of the risk of misuse and diversion (for 
more, see the endnote on page 8).
These drugs may be considered in specific situations 
where other therapy (at appropriate doses) has failed 
and the risks of misuse and dangerous adverse effects 
have been assessed. If pregabalin is used it should be 
prescribed as a twice-daily dose; gabapentin needs to 
be given three times daily.
Patients arriving in custody may have a documented 
history of significant neuropathic pain, be established 
on pregabalin and have clinically demonstrated poor 
analgesic response to other therapies. These patients 
may be considered for continued pregabalin or 
gabapentin prescribing after carefully assessing their 
pain and previous drug therapies.
Drugs should be titrated to an effective dose range 
(see appendix): ‘start low, go slow’ is a good principle. 
If there is no perceptible benefit after four weeks 
of titrating, taper the drug and stop. (Also consider 
amitriptyline for non-neuropathic pain, particularly if 
the clinical team has evidence that suggests nocturnal 
symptoms are impairing sleep.) If neuropathic pain 
of well-defined origin is refractory to optimal doses of 
tricyclic antidepressants or antiepileptic drugs, consider 
a trial of opioid therapy (see suggested treatment 
pathway).
Opioids for persistent pain: key points
• The WHO analgesic ladder has poor applicability 
in treating persistent non-cancer pain
• Evidence for opioids’ effectiveness in managing 
long-term pain is lacking, particularly in relation 
to important functional outcomes
• Opioid therapy should support other pain 
management strategies e.g. physiotherapy
• If doses of 120mg morphine equivalent/day do 
not achieve useful relief of symptoms, the drug 
should be tapered and stopped
• All opioids (strong and weak) should be 
prescribed with caution
• There is no evidence that any opioid produces 
superior pain relief to morphine
• Sustained release opioid preparations can be 
used for most cases
• Fast-acting preparations are unsuitable to treat 
persistent pain
• Methadone is an established way of treating 
long-term pain. For patients with pain who also 
receive methadone substitution, pain can be 
treated by maintaining an effective daily dose in 
two divided increments
• When converting from one opioid to another, 
ratios should be cautious and the effect 
monitored. Conversion ratios between opioids 
vary substantially, particularly for methadone.
Pharmacoptherapy for neuropathic pain:  
key points
• Medications are the best way to treat 
neuropathic pain but fewer than a third of 
patients will respond
• Pain relief from neuropathic pain medications 
is modest
• Tricyclic antidepressants are the most effective 
treatment for neuropathic pain
• Carbamazepine may be effective
• Gabapentin and pregabalin are unsuitable as 
first-line drugs in secure environments.
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2.1.6 Pharmacological management of chronic 
visceral pain and poorly defined disorders
These respond poorly to medication although there 
is some evidence for using tricyclic antidepressant 
drugs in treating pain associated with irritable bowel 
syndrome. Psychological-based interventions 
including physiotherapeutic treatment are more 
effective for managing these disorders.
2.2 Non-pharmacological management of 
pain
2.2.1 Psychological interventions
Addressing patient’s fears and mistaken beliefs about 
the causes and implications of pain requires good 
information, and possibly cognitive and behavioural 
intervention. For example, people often believe that 
back pain indicates serious degeneration that will 
end in immobility and loss of independence unless 
they are cautious about using their backs. Over-
caution, instead of the pain itself, is more likely to lead 
to disability. Information and education often needs 
support from a demonstration (guided by a physical 
therapist) that using the back more will strengthen 
rather than weaken it.
Depression should be treated in the context of pain, with 
no assumption that relieving depression will abolish pain. 
Attributing pain to anxiety, depression or psychosomatic 
processes is unhelpful and poorly supported. Pain 
and psychological disorders should be diagnosed 
on positive evidence, and treated appropriately in the 
context of multiple problems. Anxiety, depression and 
stress all worsen the experience of pain and can be 
barriers to successful pain management. Rehabilitation 
and progress towards participation are best achieved 
jointly with physiotherapeutic support or intervention. 
The aim is effective self-management rather than long-
term therapy.
2.2.2 Physical rehabilitation
Good evidence supports active techniques, such as 
exercise classes, working towards activity goals and 
better health,in managing pain. These techniques 
are best combined with cognitive and behavioural 
interventions and need to be individually adjusted to 
set a realistic baseline and rate of progress.
Evidence for other non-pharmacological physical 
interventions is poor, but techniques such as 
acupuncture and TENS are common. No strong 
evidence supports them but they may help patients 
self-manage their pain without medication.
Note that pharmacotherapy has little role in managing 
simple, persistent mechanical lower back pain. The 
mainstays of therapy are physical rehabilitation and 
interventions to address mistaken beliefs about the 
causes of pain and the association between pain and 
activity. Patients with more complex presentations, e.g. 
those who have had multiple spinal surgery, may need 
additional interventions including opioid medication 
and specialist advice may be needed.
Non-pharmacological management of pain:  
key points
• Fears and mistaken beliefs about the causes 
and consequences of pain must be addressed
• Co-morbid depression and other psychological 
disorders need treating as part of pain 
management
• Good evidence supports active physical 
techniques in managing pain
• Physical rehabilitation is best combined with 
cognitive and behavioural interventions
• Interventions such as TENS and acupuncture 
are poorly supported by evidence for benefit 
but may support self-management of pain.
Visceral pain and poorly defined disorders:  
key points
• Psychological interventions are mainstays of 
managing visceral pain and poorly defined 
disorders
• Tricyclic antidepressant drugs may help to 
manage pain linked to irritable bowel syndrome.
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Endnote
Healthcare professionals have consistently observed 
gabapentin and pregabalin misuse in secure environments 
for some years, and pregabalin has been identified as a 
possible contributor to death in custody (published data 
highlights the potential for misuse – see further reading 
Schwan et al). Both drugs have a significant number of 
adverse effects with a frequency of ‘common’ or higher. 
These include psychiatric and gastrointestinal effects and 
many clinically important others at a lower incidence. 
Adverse effects are additive when co-prescribed with other 
drugs acting on the CNS, particularly opioids. Bioavailability 
of gabapentin decreases as the dose increases whereas 
pregabalin’s is largely independent of dose, which explains 
the increased risk of high dose pregabalin use. The adverse 
effect profile and potential for misuse make gabapentin and 
pregabalin potentially problematic in secure environments 
and these drugs should not ordinarily be used as first line 
therapy.
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Process of  
preparation
Members of the consensus group were identified 
following a three-month period of communication 
between representatives of professional stakeholder 
organisations, policy makers and providers of clinical 
care in secure environments. The scope of the project 
has been informed by current challenges identified by 
stakeholder individuals and organisations. Members 
of the consensus group met in Bristol on 9 February 
2012. The consensus group subsequently finalised 
this clinical best practice statement and derived the 
accompanying clinical pathways.
Implementation of this document has been supported 
by information sessions fo prison healthcare and 
other stakeholder groups. The consensus group, pain 
professionals and Public Health England will continue to 
work collaboratively to deliver high-quality healthcare to 
patients with pain in secure environments.
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Appendix 1
SUGGESTED DOSING FOR COMMONLY USED DRUGS IN TREATING NEUROPATHIC PAIN 
(Start all drugs at a low dose with at least one week between dose increments: the figures below represent the  
starting dose and a suggested upper dose limit)
DRUG  DOSE
Amitriptyline 10-75mg once daily
Nortriptyline 10-75mg once daily
Duloxetine 60-120mg once daily
Carbamazepine 200-1200mg daily in two divided doses
Gabapentin 900-2700mg daily in three divided doses
Pregabalin 150-600mg daily in two divided doses
If pregabalin needs to be withdrawn, reduce the daily dose gradually at a maximum of 50-100mg/week. Withdraw 
gabapentin at a maximum rate of 300mg daily dose every four days.
TRANSDERMAL OPIOIDS: APPROXIMATE EQUIVALENCE WITH ORAL MORPHINE
Oral morphine equivalent (mg/24-hours) 10 15 30 45 60 90 120 180 270 360
Transdermal buprenorphine (µg/hr)   5 10 20 35 52.5   70
Transdermal fentanyl (µg/hr) 12 25   50   75 100
Published conversions ratios vary and these figures are a guide only. Morphine equivalences for transdermal opioid 
preparations have been approximated to allow comparison with available preparations of oral morphine. 
Appendix 2
From: The British Pain Society 2010 ‘Opioids for persistent pain: good practice’. (Available from www.britishpainsociety.org/pub_professional.htm#opioids). 
Accessed June 2013.
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Appendix 3. Suggested treatment pathways 
Assessing and initiating pain management 
Patient presents with pain
Assess pain, including:  
• History of onset/inciting events 
• Current symptom description 
• Exacerbating and relieving influences 
• Effect of pain on function including sleep 
• Previous treatments for pain 
• Current medication (confirm from previous HCP) 
• Medical/surgical history 
• Mental health history including substance misuse 
• Social history 
• Patient’s understanding of symptoms 
History suggests: 
• Obvious precipitating event (trauma/tissue damage) 
• Evidence of functional impairment
History and examination confirm 
diagnosis of neuropathic pain
Previous healthcare 
provider confirms pre-
existing persistent pain 
condition
Initiate paracetamol +/- NSAIDs
Consider active physiotherapeutic strategies (paced 
increase in exercise) supported by education about 
meaning and consequences of pain
Consider night-time amitriptyline if sleep disturbed by 
pain
For refractory cases of well-defined pain consider 
opioid therapy
Manage depression and other psychological disorder in accordance with local guidance
Initiate amitriptyline 10mg nocte increasing every 
few days as tolerated to 75mg nocte. If sedation a 
problem change to equivalent dose of nortriptyline
If no response to tricyclic antidepressants use anti-
epileptic drugs starting with carbamazepine. For 
refractory cases of neuropathic pain of confirmed 
origin consider opioid therapy
YesNo
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Appendix 3. Suggested treatment pathways 
Opioid therapy guidance pathway
For all patients
Previous healthcare 
provider confirms pre- 
existing persistent pain 
condition
Manage depression and other psychological disorder in accordance with local guidance
Consider opioid treatment for
•  Severe osteoarthritis 
•  Pain following multiple spinal surgery
• Neuropathic pain unresponsive to tricyclic   
 antidepressants/antiepileptic drugs
Yes
No
Consider active physiotherapeutic strategies (paced increase in exercise) supported by education about meaning and 
consequences of pain
Discuss harm of long-term opioids, including 
limited efficacy, endocrine and immune effects, and 
hyperalgesia
Initiate time-constrained trial of opioid therapy. 
• Define goals of therapy 
• If symptoms not relieved and functional goals not  
 met after three upwards dose adjustments, taper  
 and stop opioids
Start once-daily morphine 20mg and review regularly 
for upwards dose titration
If no substantial pain relief or functional improvement 
at 120mg morphine equivalent/24 hours taper drug 
and stop
History suggests: 
• Obvious precipitating event (trauma/tissue
 damage) 
• Evidence of functional impairment
Suspend methadone 
taper and give daily 
dose of methadone in 
two divided doses
Convert to once daily 
morphine starting with 
conservative conversion 
(methadone 1mg = 
morphine 2mg) and 
review regularly for 
upwards dose titration
If dose of morphine 
exceeds 120mg/24 
hours, consider gradual 
taper once conversion 
complete
Reassess pain as 
above with history and 
examination
Patient established on methadone complains of pain 
on dose reduction
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